SPLISubstance P-Like Immunoreactivity
SPLISustainable Public Lighting Initiative (Australia)
SPLISubstance P-Like Immunofluorescence
References in periodicals archive ?
SPLI will issue 7,500,000 shares of its newly created Series B Preferred stock (convertible to common shares at 100:1 and restricted for 18 months) for 100% of the issued shares of Vapor Group, Inc.
A full report on SPLI that includes risk factors, industry review, financial position, potential revenues, and review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link: